NUVB - Nuvation Bio Announces FDA Approval of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in TKI-Naïve Advanced ROS1- Positive Non-Small Cell Lung Cancer
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.